Search results for Gilead Sciences

<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.

Gilead Sciences Is Doubling Down On Acquisitions

WHO and Gilead Sciences renew partnership to accelerate visceral leishmaniasis elimination

The World Health Organization (WHO) and Gilead Sciences have renewed their partnership through a new five-year agreement (2026–2030) to support the elimination of visceral leishman...

Gilead projects $107M Q1 earnings headwind due to recent R&D deals

Gilead Sciences launches bond offering after acquisition spree - Bloomberg

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis

Gilead Sciences’ Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs coul...

Gilead cancels midstage HIV trial as FDA’s clinical hold remains intact

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials.

Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline

Gilead has struck a deal to buy Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward p...

<![CDATA[Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson &...

Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV

We take a closer look at Gilead's pipeline strategy and dealmaking activity in 2026 as the company attempts to broaden its focus beyond HIV. The post Gilead’s pipeline strategy in...

Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs

Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets

Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities

Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies. The companies said Tubul...

ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’

The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront e...

Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics’ preclinical anticancer...

Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't

leadership change at gilead

leadership change at gilead Anonymous (not verified) Mon, 05/18/2026 - 08:33 field_thread_url https://cafepharma.com/boards/threads/leadership-change-at-gi...

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs

Gilead Sciences has sued several New York City pharmacies claiming they sold counterfeit HIV medication bearing the Gilead brand.

With 3 quick buyouts, Gilead leans into its latest transformation

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it’s long strug...

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost

With Gilead's $7.8 billion buyout of Arcellx complete, the California pharma is consolidating some of the workforce at the acquired company.